INVITED SPEAKERS 2009

Craig Allred, St. Louis, MO, USA
The estrogen receptor and breast cancer

Mario Amendola, Milan, Italy
New lentiviral vectors for co-ordinate transgene expression and multiple miRNA/siRNA delivery

Eelco van Anken, San Francisco, CA, USA
Endoplasmic reticulum stress signaling from oligomeric Ire1

Cecile Arrieumerlou, Basel, Switzerland
Spatial propagation of pro-inflammatory signals during bacterial infection

David Baltimore, Pasadena, CA, USA
MicroRNAs in inflammation and cancer

Boris Bastian, San Fransisco, CA, USA
Genetic diversity in melanoma: implications for disease classification and therapy

Patrick Bauerle, Munchen, Germany
Cancer therapy by T cell-engaging antibody constructs

Boudewijn Burgering, Utrecht, The Netherlands
FOXO transcription factors, mediators of oxidative stress in lifespan and disease

Stephen Baylin, Baltimore, MD, USA
The cancer epigenome: towards epigenetic therapy

Peter Carmeliet, Leuven, Belgium
Oxygen sensors as regulators of tumor vessel morphogenesis

Karen Cichowski, Boston, MA, USA
Unexpected mechanisms of Ras activation in metastatic prostate cancer and gliomagenesis: epigenetics and more

Lena Claesson-Welsh, Uppsala, Sweden
Signal transduction in angiogenesis

George Cotsarelis, Philadelphia, PA, USA
Cutaneous epithelial stem cells and skin regeneration

Lisa Coussens, San Francisco, CA, USA
Pro-tumor immunity and solid tumor development

Kylie Creig, Parkville, Victoria, Australia
The transcription factor c-Myb is essential for early B cell development

Peter Creswell, New Haven, CT, USA
Antigen cross-presentation: how do external proteins get in?

Jeroen Demmers, Rotterdam, The Netherlands
Functional proteomics of gene regulation networks

Eric Deutsch, Villejuif, France
Overview of thoracic models developed at IGR

Julian Downward, London, UK
Ras and PI 3-kinase signaling networks in cancer

Laura Esserman, San Francisco, CA, USA
ISPY2, a targeted drugs neo-adjuvant adaptive trial design

Sydney Evans, Philadephia, PA, USA
What we can learn about tumor physiology and clinical behavior from tumor oxygen maps

Dean Felsher, Stanford, CA, USA
Molecular and mathematical modeling of oncogene addiction

Michael Feuerstein, Bethesda, MD, USA
Cognitive limitations and work performance in occupationally active brain and breast cancer survivors

Riccardo Fodde, Rotterdam, The Netherlands
Cancer stem cells: are you a Feyenoord or Ajax supporter?

Margaret Frame, Edinburgh, UK
Focal adhesion kinase in integrin signalling and disease

Iain Fraser, Bethesda, MD, USA
Analysis of mammalian signaling networks: lessons from a research consortium

Helge Grosshans, Basel, Switserland
Life and death of microRNAs - genetic-biochemical dissection of miRNA pathways

Jun-Lin Guan, Ann Arbor, MI, USA
Integrin signaling through FAK in mammary stem cells and breast cancer

Iain Hagan, Manchester, UK
Coordinating cell division by integrating signaling networks at the centrosome/spindle pole

Adriana Haimovitz-Friedman, New York, NY, USA
A ceramide rheostat balances angiogenesis and anti-angiogenesis

Per Hall, Stockholm, Sweden
Incidence and prognosis of contralateral breast cancer

Harald Herrmann, Heidelberg, Germany
Structure and organization of nuclear lamin filaments: Impact of laminopathic mutations

Steve Jackson, Cambridge, UK
Cellular responses to DNA damage: molecular insights and new strategies for cancer therapy

Penny Jeggo, Brighton, UK
Impact of heterochromatin on DNA repair and damage response signalling

Wilhelm Krek, Zürich, Switserland
VHL: linking microtubules to primary cilia maintenance, chromosome stability and tumour suppression

Toby Lawrence, London, UK
Re-educating tumour-associated macrophages

Fred van Leeuwen, Amsterdam, the Netherlands
Chromatin dynamics

Michael Leitzmann, Regensburg, Germany
Adiposity and cancer from an epidemiologic perspective

Zvi Livneh, Rehovot, Israel
Molecular insight into error-prone DNA repair in mammalian cells: A mutagenic process that protects us against cancer

Yohan Loriot, Villejuif, France
BCL2 targeting using an antisense in a SCLC model

Christian Luber, Munich, Germany
In vivo-proteomics: Label-free analysis and dendritic cell subsets

Matthias Mann, Martinsried, Germany
Technology of SILAC-based quantitative teomics and potential clinical applications

Muriel Moser, Brussels, Belgium
Naturally occurring regulatory T cells control the CD70/CD27 pathway of T helper 1 cell differentiation

Paolo Michieli, Torino, Italy
Control of invasive growth in physiology and disease by scatter factors and their tyrosine kinase receptors

Pierre Mordant, Villejuif, France
Dual blockade of mTor and RAF pathways in NSCLC

Harold Moses, Nashville, TN, USA
TGF-beta regulation of the tumor microenvironment

Andrea Musacchio, Milan, Italy
Feedback control of mitosis

Marcin Nowotny, Warsaw, Poland
Structural studies of RNases H – from substrate binding to catalysis

Stefan Offermans, Heidelberg, Germany
Biological roles of heterotrimeric G-proteins revealed by genetic mouse models

Håkan Olsson, Lund, Sweden
Risk factors and tumor biology of breast cancer

Michele de Palma, Milan, Italy
Monocyte and macrophage heterogeneity in blood and tumor microenvironment

Peter Parker, London, UK
PKC and the control of spatially resolved signals

Salvatore Pece, Milan, Italy
The molecular profile of mammary stem cells provides a new outlook on the cellular and molecular heterogeneity of breast cancers

Helen Pickersgill, Vienna, Austria
An insider's guide to getting your paper published: Insights from a Science editor

David Piwnica-Worms, St. Louis, MO, USA
Dynamic molecular imaging of signal transduction pathways in vivo

Helen Piwnica-Worms, St. Louis, MO, USA
Translation of fundamental cell cycle principles to novel breast cancer treatments

Hidde Ploegh, Cambridge, MA, USA
Immune technology

Jeff Pollard, New York, NY, USA
Macrophages promote tumor progression and metastasis

Sandro Prato, Melbourne, Australia
Analysis of the mechanisms involved in the impairment of tumour- specific CD8 T cells in a mouse model of non-Hodgkin lymphoma

Alain Puisieux, Lyon, France
Inactivation of safeguard mechanisms by Twist oncoproteins

Anne Ridley, London, UK
Rho GTPases and signalling in cell migration

Rafael Rosell, Barcelona, Spain
Prospective studies in the adjuvant and metastatic settings of non-small-cell lung cancer: The Spanish Lung Cancer Group SCAT and BREC trials (emphasis on EGFR mutation status)

Lenhard Rudolph, Ulm, Germany
Checkpoint response to telomere dysfunction in aging stem cells

Fred de Sauvage, San Francisco, CA, USA
Targeting the hedgehog pathway in cancer: from bench to clinic

Wulf Schneider, Regensburg, Germany
TNF internalisation and adenovirus inhibition of TNF-mediated apoptosis

Joachim Schulze, Bonn, Germany
At the cross roads of genomics and the tumor microenvironment: How can we use genomic technologies to decipher inhibitory networks in the tumor microenvironment

Peter Sicinski, Boston, MA, USA
Requirement for cyclin A function in stem cells

Marc Symons, New York, NY, USA
Role of Rho family GTPases in tumor invasion

Li-Huei Tsai, Cambridge, MA, USA
Epigenetic regulation of memory formation in health and disease

Michiel Vermeulen, Utrecht, The Netherlands
Applying high accuracy quantitative mass spectrometry to study epigenetic (de-)regulation of gene expression

Karen Vousden, Glasgow, Scotland, United Kingdom
Functions of p53 in tumour suppression and progression

Yosef Yarden, Rehovot, Israel
EGFR and HER2 in cancer: signaling networks and targets for therapy

Jon Yewdell, Bethesda, MD, USA
Serendipity strikes again: Adventures in MHC Class I antigen processing lead to discovery of methionine tRNA misacylation

Lars Zender, Hannover, Germany
Integrative oncogenomic approaches for accelerated cancer gene discovery in hepatocellular carcinoma